Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

7.840 -0.100 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,382,428
Open 7.570
Bid (Size) 7.870 (3)
Ask (Size) 7.920 (8)
Prev. Close 7.940
Today's Range 7.480 - 7.885
52wk Range 4.540 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and CASY stocks rise. 
Via Benzinga

Performance

YTD
-20.57%
-20.57%
1 Month
-24.03%
-24.03%
3 Month
-23.36%
-23.36%
6 Month
+41.26%
+41.26%
1 Year
+57.75%
+57.75%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Where Will Recursion Pharmaceuticals Be in 5 Years?
Via The Motley Fool
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Via Benzinga
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
Via Benzinga
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Via The Motley Fool
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI Surge Ending: Only One Category Was Up This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Via Benzinga
Recursion Publishes Annual Environmental, Social and Governance Report
From Recursion Pharmaceuticals
Via GlobeNewswire
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
Via Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Announces Plans to Open New Office in London
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.